secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001140361-25-039650
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength
--------------------------------------------------------------------------------

- TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.
- Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.
- Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.
- Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.
- Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/0001140361-25-039650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/ef20057869_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-039650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer